Abbott Laboratories has tightened its target ranges for adjusted EPS and organic sales growth (excluding Covid-19 test revenues), to $4.55-4.70 and 8.5-10% respectively, for the current year.

For the first three months of 2024, it reports adjusted EPS of $0.98, down 4.9% year-on-year, despite revenues up 2.2% to $9.96 billion 'thanks to the solid performance of underlying core businesses'.

On an organic basis and excluding sales linked to Covid-19 tests, the healthcare group's quarterly sales rose by 10.8%, representing its fifth consecutive quarter of double-digit growth.

Copyright (c) 2024 All rights reserved.